시장보고서 | 연간정보서비스 | 맞춤형시장조사 | 메일링 | 샘플 요청 목록
세계의 암 진단용 AI 시장 보고서(2025년)
AI In Cancer Diagnostics Global Market Report 2025
상품코드 : 1824565
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 250 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ￦ 6,482,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ￦ 9,370,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ￦ 12,257,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

암 진단용 AI 시장 규모는 향후 수년간 비약적인 성장이 예상됩니다. 2029년에는 16억 5,000만 달러로 성장하며, CAGR은 20.0%를 나타낼 전망입니다. 예측 기간의 성장은 설명 가능한 AI의 출현, 건강 관리 지출의 세계적 증가, 전자 의료 기록(EHR)과의 통합, 맞춤형 의료의 채택, AI 알고리즘의 지속적인 발전으로 인해 발생합니다. 예측 기간의 주요 동향으로는 이미징 기술의 진보, 기술적 융합, 헬스케어와 하이테크 기업의 협업, 디지털 병리학의 대두, 병리 조직 검사의 자동화 등이 있습니다.

향후 5년간의 성장률 20.0%라는 예측은 전회 예측으로부터 0.1%의 소폭의 감소를 반영하고 있습니다. 이 감소는 주로 미국과 다른 국가 간의 관세의 영향 때문입니다. 관세 장벽은 영국과 캐나다에서 공급되는 AI 탑재 병리 조직 검사 스캐너와 유전체 분석 소프트웨어의 비용을 상승시킴으로써 미국 시장을 저해하고 정밀 종양학의 채용을 지연시키고 병리 검사실 지출을 상승시킬 것으로 예측됩니다. 또한 상호관세와 무역의 긴장과 한계 증가로 인한 세계경제와 무역에 대한 악영향으로 인해 그 영향이 더욱 광범위해질 것으로 보입니다.

암 유병률의 상승은 암 진단용 AI의 성장을 가속할 것으로 예측됩니다. 암은 신체의 다른 부분에 침입하거나 전이하는 비정상적인 세포 증식을 특징으로 하는 질환군을 말합니다. 암 치료에서 AI의 통합은 효율성, 정확성, 맞춤 치료 옵션을 개선하고 궁극적으로 암 환자의 결과를 향상시키는 것을 목표로 합니다. 예를 들어 2024년 5월 미국 정부기관인 국립암연구소는 2024년 미국에서 새롭게 약 200만명의 암 환자가 진단되어 61만 1,000명 이상 사망했다고 밝혔습니다. 2040년까지 세계 신규 암 환자는 2,990만명으로 증가하고, 암 관련 사망은 1,530만명에 달할 것으로 예측되고 있습니다. 그 결과, 암 유병률 증가가 암 진단용 AI의 채용을 촉진하고 있습니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 : 금리, 인플레이션, 지정학, 무역전쟁과 관세, 그리고 코로나 및 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별/국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 프로파일

제31장 기타 주요 기업 및 혁신 기업

제32장 세계 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장의 잠재력이 높은 국가, 부문, 전략

제36장 부록

KTH
영문 목차

영문목차

AI in cancer diagnostics involves employing artificial intelligence technologies such as machine learning and deep learning to analyze medical images, genetic data, or patient histories for aiding in the early detection, diagnosis, and prognosis of cancer. These systems can detect patterns and anomalies in data that may elude human perception, thereby enhancing diagnostic accuracy and efficiency.

The primary components of AI in cancer diagnostics include software solutions, hardware, and services. Software solutions utilize artificial intelligence (AI) and machine learning (ML) technologies to enhance the accuracy and efficiency of cancer detection, prognosis, and treatment selection. Various types of cancer, including breast cancer, lung cancer, brain tumors, skin cancer, cervical cancer, prostate cancer, colorectal cancer, and others, are addressed. These applications encompass screening and diagnosis, tumor identification, and monitoring, and are utilized by a range of end-users such as hospitals, diagnostic centers, medical research institutes, and contract research organizations.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.

The AI in cancer diagnostics market research report is one of a series of new reports from The Business Research Company that provides AI in cancer diagnostics market statistics, including AI in cancer diagnostics industry global market size, regional shares, competitors with an AI in cancer diagnostics market share, detailed AI in cancer diagnostics market segments, market trends, and opportunities, and any further data you may need to thrive in the AI in cancer diagnostics industry. This AI in cancer diagnostics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The ai in cancer diagnostics market size has grown exponentially in recent years. It will grow from $0.66 billion in 2024 to $0.79 billion in 2025 at a compound annual growth rate (CAGR) of 21.0%. The growth in the historic period can be attributed to increasing cancer incidence rates, data explosion in healthcare, supportive regulatory environment, focus on precision medicine, expansion of AI applications beyond imaging.

The ai in cancer diagnostics market size is expected to see exponential growth in the next few years. It will grow to $1.65 billion in 2029 at a compound annual growth rate (CAGR) of 20.0%. The growth in the forecast period can be attributed to emergence of explainable AI, global increase in healthcare it spending, integration with electronic health records (EHR), personalized medicine adoption, continued advances in AI algorithms. Major trends in the forecast period include advancements in imaging technologies, technological convergence, collaborations between healthcare and tech companies, rise of digital pathology, automation in histopathology.

The forecast of 20.0% growth over the next five years reflects a slight reduction of 0.1% from the previous projection. This reduction is primarily due to the impact of tariffs between the US and other countries. Tariff barriers are expected to hamper the U.S. market by increasing the cost of AI-powered histopathology scanners and genomic analysis software sourced from the UK and Canada, thereby slowing precision oncology adoption and elevating pathology lab expenditures. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The rising prevalence of cancer is expected to drive the growth of artificial intelligence in the cancer diagnostics market. Cancer refers to a group of diseases characterized by abnormal cell growth that can invade or spread to other parts of the body. The integration of AI in cancer care aims to improve efficiency, accuracy, and personalized treatment options, ultimately enhancing outcomes for cancer patients. For example, in May 2024, the National Cancer Institute, a US-based government agency, projected that approximately 2 million new cancer cases would be diagnosed in the U.S. in 2024, with over 611,000 deaths expected. By 2040, global new cancer cases are anticipated to rise to 29.9 million, with cancer-related deaths reaching 15.3 million. As a result, the growing prevalence of cancer is driving the adoption of artificial intelligence in the cancer diagnostics market.

Leading companies in the AI in cancer diagnostics market are experiencing notable growth driven by advancements in AI-powered digital pathology solutions for cancer diagnosis. These solutions utilize AI algorithms to detect cancer and other diagnostic features in various tissue types, offering accurate and timely cancer diagnosis, supporting case prioritization, and ensuring reproducible diagnoses. For instance, in November 2023, Dedalus & Ibex Medical Analytics introduced an integrated End-to-End AI-powered digital pathology solution for cancer diagnosis across Europe. This solution aims to enhance accuracy, provide AI-powered decision support tools, streamline reporting, improve laboratory efficiency, and boost diagnostic confidence.

In December 2023, Lunit, a South Korean AI company, acquired Volpara for $193 million, aiming to establish the combined entity as a leading force in AI-driven cancer diagnostics, particularly in the U.S. market. Volpara's extensive presence in over 2,000 medical sites across the U.S. and its vast database of over 100 million high-quality mammogram images position it as a valuable addition to Lunit's capabilities. Volpara, based in New Zealand, specializes in providing AI-powered software for personalized screening and early detection of breast cancer.

Major companies operating in the AI in cancer diagnostics market report are Microsoft Corporation, IBM Corporation, Babylon Healthcare Services Ltd., Verily Life Sciences LLC, Tempus, Guardant Health, Lunit Inc., Paige AI Inc., Ada Health GmbH, Viz.ai Inc., Butterfly Network Inc., Insilico Medicine, BenevolentAI SA SA, Enlitic Inc., Ibex Medical Analytics, Kheiron Medical Technologies Limited, CureMetrix Inc., CancerIQ Inc., MultiplAI Health, Freenome Holdings Inc., SkinVision, Entopsis, Owkin, Imagen Technologies, Panakeia Technologies, EchoPixel Inc., X-Zell Inc., Cyrcadia Health, Oncora Medical, Xilis

North America was the largest region in the artificial intelligence in cancer diagnostics market in 2024. The regions covered in the AI in cancer diagnostics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the AI in cancer diagnostics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain

AI in the cancer diagnostics market consists of revenues earned by entities by providing services such as early detection and screening, image analysis and interpretation, predictive analytics, and treatment planning. The market value includes the value of related goods sold by the service provider or included within the service offering. The AI in Cancer Diagnostics market also consists of sales of medical imaging devices, pathology analysis systems, genomic sequencing equipment, and patient monitoring devices that are used in providing services. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

AI In Cancer Diagnostics Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on ai in cancer diagnostics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for ai in cancer diagnostics ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The ai in cancer diagnostics market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

Scope

Table of Contents

1. Executive Summary

2. AI In Cancer Diagnostics Market Characteristics

3. AI In Cancer Diagnostics Market Trends And Strategies

4. AI In Cancer Diagnostics Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global AI In Cancer Diagnostics Growth Analysis And Strategic Analysis Framework

6. AI In Cancer Diagnostics Market Segmentation

7. AI In Cancer Diagnostics Market Regional And Country Analysis

8. Asia-Pacific AI In Cancer Diagnostics Market

9. China AI In Cancer Diagnostics Market

10. India AI In Cancer Diagnostics Market

11. Japan AI In Cancer Diagnostics Market

12. Australia AI In Cancer Diagnostics Market

13. Indonesia AI In Cancer Diagnostics Market

14. South Korea AI In Cancer Diagnostics Market

15. Western Europe AI In Cancer Diagnostics Market

16. UK AI In Cancer Diagnostics Market

17. Germany AI In Cancer Diagnostics Market

18. France AI In Cancer Diagnostics Market

19. Italy AI In Cancer Diagnostics Market

20. Spain AI In Cancer Diagnostics Market

21. Eastern Europe AI In Cancer Diagnostics Market

22. Russia AI In Cancer Diagnostics Market

23. North America AI In Cancer Diagnostics Market

24. USA AI In Cancer Diagnostics Market

25. Canada AI In Cancer Diagnostics Market

26. South America AI In Cancer Diagnostics Market

27. Brazil AI In Cancer Diagnostics Market

28. Middle East AI In Cancer Diagnostics Market

29. Africa AI In Cancer Diagnostics Market

30. AI In Cancer Diagnostics Market Competitive Landscape And Company Profiles

31. AI In Cancer Diagnostics Market Other Major And Innovative Companies

32. Global AI In Cancer Diagnostics Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The AI In Cancer Diagnostics Market

34. Recent Developments In The AI In Cancer Diagnostics Market

35. AI In Cancer Diagnostics Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기